Z 203

Drug Profile

Z 203

Alternative Names: 0632; T 0632

Latest Information Update: 31 Oct 2005

Price : $50

At a glance

  • Originator Tanabe Seiyaku
  • Developer Tanabe Seiyaku; Zeria
  • Class
  • Mechanism of Action Cholecystokinin A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Pancreatitis

Most Recent Events

  • 31 Oct 2005 Discontinued - Phase-I for Pancreatitis in Japan (IV)
  • 01 Aug 2000 A study has been added to the pharmacokinetics section
  • 26 Jun 1999 Phase-I clinical trials for Pancreatitis in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top